Aptorum Group Limited - Class A Ordinary Shares (APM) News
Filter APM News Items
APM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APM News Highlights
- APM's 30 day story count now stands at 3.
- Over the past 8 days, the trend for APM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest APM News From Around the Web
Below are the latest news stories about APTORUM GROUP LTD that investors may wish to consider to help them evaluate APM as an investment opportunity.
APM Stock: Is It Worth Investing In APM?Aptorum Group is a clinical-stage biopharmaceutical company based in the UK, dedicated to the exploration, development, and commercialization of therapeutic assets for the treatment of diseases with unmet medical needs. |
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023NEW YORK & LONDON, December 22, 2023--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. |
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of ShareholdersNEW YORK & LONDON, December 21, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. |
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023NEW YORK & LONDON, November 16, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on Decem |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning! |
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital MarketsNEW YORK, August 10, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockhold |
10 Oversold Global Stocks To BuyIn this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like July, August is full of surprises on the data front. After the U.S. economy grew quite […] |
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaNEW YORK & LONDON & PARIS, June 22, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA. The Phase 1b/2a study of SACT-1 submitted is for the combination with |
Aptorum Group Limited Announces Voluntary Delisting from Euronext ParisNEW YORK & LONDON & PARIS, June 09, 2023--Regulatory News: Aptorum Group Limited (the "Company") (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the "Aptorum Shares") (ISIN KYG6096M1226) from Euronext Paris. The Board of Euronext has approved this request. |
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity DeficiencyNEW YORK & LONDON & PARIS, May 05, 2023--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockhold |